Potential obesity breakthrough boosts Marcadia

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Marcadia Biotech is now on the radar screen.

CEO Fritz French thinks the publication of the Carmel company’s
research on obesity-fighting compounds by the major scientific journal *Nature Chemical Biology will grab attention of scientists
and other drug companies around the world.“It gets us more exposure to large pharma companies collaborating down the
road — on other things,” French said. The *Nature article involved Marcadia’s collaborative work with New
Jersey-based drug giant Merck & Co. Inc. But the Carmel-based biotech firm has several other obesity and diabetes-fighting
drugs in its pipeline.

“All of these things add to your credibility and image,” French said.

*Nature Chemical Biology is a sister publication of the widely known journal *Nature.

The *Nature article demonstrated
the elimination of obesity in rodents in one week with an injection of Marcadia-developed molecules. The molecules, licensed
from Indiana University, combine some of the protein sequence of two naturally occurring hormones that regulate
blood sugar, glucagon and glucagon-like-peptide-1.

The novel combination had a big impact on the mice used in tests
of the drug. Marcadia’s researchers found that a single injection of their best molecule in mice decreased body weight
by 25 percent and fat mass by 42 percent after one week. Repeated treatment had even greater effect.

“The
results that we saw in these animal models were unprecedented,” French said.

Marcadia and Merck will move
the experimental molecules into human trials, which will cost hundreds of millions of dollars to take all the way to market.
And it may not get there. Plenty of experimental drugs have shown great promise in animals only to fail in humans.

But the buzz about Marcadia’s potential breakthrough could help the company with future fund-raising needs. To date,
the 3-year-old company has raised $16 million in venture capital.

It has 10 employees and works closely with researchers
at IU, who toil under Marcadia co-founder Richard DiMarchi. DiMarchi and University of Cincinnati physician
Matthias Tschöp were the co-lead authors of the *Nature article.

“It is an important milestone for the
company to get this external validation,” French said. “We’ve been relatively under the radar of a lot of
people until now.”•

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In